Physician profile
Roscoe Nelson
NPI 1962487462
$151,508.40
in general payments reported to CMS, 2019-2025
50 companies · $18K in 2025
The $18K reported for 2025 was more than what 96% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,106 · 2020: $578 · 2021: $2,203 · 2022: $16K · 2023: $80K · 2024: $34K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $111K · Travel and Lodging: $12K · Food and Beverage: $8,511 · Education: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $110,644.25 |
| Travel and Lodging | $11,921.97 |
| Food and Beverage | $8,510.94 |
| Education | $193.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $133,029.60 | 2021-2025 | Aquabeam Robotic System, Aquabeam System |
| Dendreon Pharmaceuticals LLC | $6,831.50 | 2019-2024 | Provenge |
| Boston Scientific Corporation | $2,239.49 | 2019-2025 | Axonics, Spaceoar Vue System - 10ml, Rezum Generator |
| Axonics, INC. | $1,812.94 | 2020-2024 | Axonics, Bulkamid |
| Bayer Healthcare Pharmaceuticals INC. | $1,097.00 | 2019-2025 | |
| Pfizer INC. | $742.46 | 2019-2024 | |
| Astellas Pharma US INC | $684.00 | 2019-2025 | Xtandi |
| Janssen Biotech, INC. | $660.58 | 2019-2025 | Erleada |
| Sumitomo Pharma America, INC. | $355.28 | 2023-2024 | Orgovyx, Gemtesa |
| Myriad Genetic Laboratories, INC. | $345.38 | 2021-2024 | Prolaris |
| Merck Sharp & Dohme LLC | $330.09 | 2020-2024 | Keytruda, Lynparza |
| Neotract INC. | $316.88 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $296.47 | 2020-2024 | Lynparza |
| Blue Earth Diagnostics | $248.00 | 2019-2024 | |
| Ferring Pharmaceuticals INC. | $217.60 | 2019-2025 | Adstiladrin |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roscoe Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.